Please login to the form below

Not currently logged in
Email:
Password:

LJPC-501

This page shows the latest LJPC-501 news and features for those working in and with pharma, biotech and healthcare.

La Jolla plans filing on back of blood pressure trial data

La Jolla plans filing on back of blood pressure trial data

The ATHOS-3 study found that LJPC-501, a synthetic formulation of natural peptide called angiotensin II that regulates blood pressure, hit its primary endpoint of raising blood pressure in patients ... All told, 70% of the LJPC-501-treated group in

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics